A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer - Trial NCT06382116
Access comprehensive clinical trial information for NCT06382116 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 428 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sichuan Baili Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 3
May 01, 2024
May 01, 2026
Primary Outcome
Progression-free survival (PFS)
Summary
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate
 the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic
 non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06382116
Non-Device Trial